急性髓性白血病血清可溶性Fas和ICAM-1的水平变化及其临床意义

Clinical Study on the Level of Serum sICAM-1 and sFas in Acute Marrow Leukemia Patients

目的探讨急性髓性白血病患(AML)者血清可溶性Fas(sFas)和可溶性ICAM-1(sICAM-1)水平和病情及预后的关系。方法采用酶联免疫吸附实验检测20例对照者和27例AML患者化疗前后血清sFas与sICAM-1的水平。结果化疗前AML患者血清sFas与sICAM-1水平均高于正常对照组;化疗后获得骨髓缓解的AML患者血清sFas与sICAM-1的水平显著低于化疗前,但未获缓解者血清sFas与sICAM-1的水平与化疗前无差异;不论是化疗前还是化疗后、获得缓解或未获得缓解的AML患者血清sFas水平与sICAM-1的水平呈正相关。结论AML患者血清sFas与sICAM-1水平升高是白血病细胞逃避机体免疫攻击的重要机制,其可作为AML患者观察疗效,判断预后的指标。

Objective To investigate the levels of serum soluble ICAM -1 （sICAM-1） and soluble Fas （sFas） in acute marrow leukemia（AML） patients and it s clinical implications. Method The concentrations of sFas and sICAM-1 in the sera of AML patients and 20 healthy person before or after chemotherapy were detected by ELISA. Results The levels of sFas and sICAM-1 in AML patients before chemotherapy were higher that in normal controls.After chemotherapy, the levels of sFas and sICAM-1 in AML patients achieving bone marrow remission （BMR） were remarkably decreased, which were close to the levels in normal subjects.The levels of sFas and sICAM-1 in AML patients after chemotherapy achieving no BMR were similar to those before chemotherapy.The level of sFas was positively associated with that of slCAM-1 in AML patients whatever chemotherapy was given and whatever BMR was reached after chemotherapy. Conclusion The levels of sFas and sICAM-1 were increased in the patients with AML, which may be correlated with the immune escape of leukemia.They are related to treatment effect and prognosis.